Definium Therapeutics Inc. is a biotechnology company in the healthcare sector specializing in the discovery, development, and deployment of psychedelic-inspired medicines to address psychiatric and neurological disorders. Formerly known as MindMed, the company applies scientific rigor to psychedelics, aiming to create accessible treatments that target underlying causes rather than just symptoms, with the goal of transforming mental health care amid the ongoing crisis. Its lead candidate, DT120 Orally Disintegrating Tablet (ODT)—a form of lysergide D-tartrate—has received FDA Breakthrough Therapy Designation for generalized anxiety disorder (GAD) and is advancing through multiple Phase 3 trials for GAD and major depressive disorder (MDD), with topline data expected in 2026. The pipeline also includes early-stage programs like DT402 for autism spectrum disorder. Headquartered at One World Trade Center in New York, with regional offices in North Carolina and California, Definium Therapeutics operates as a public entity focused on evidence-based innovation to enable long-term remission and improve patient outcomes on a large scale.
See your Portfolio Score and get data driven insights in ~60 seconds.
Opens in PortfolioPilot
Based on technical indicators and chart patterns, DFTX shows...
Market sentiment analysis indicates...